Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Drug Resistance

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 87 articles:
HTML format
Text format



Single Articles


    December 2017
  1. STELLA-ASCARIZ N, Arribas JR, Paredes R, Li JZ, et al
    The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  2. WALLIS CL, Godfrey C, Fitzgibbon JE, Mellors JW, et al
    Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  3. RAIZES E, Hader S, Birx D
    Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


    November 2017
  4. NAIDOO P, Theron G, Rangaka MX, Chihota VN, et al
    The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  5. BLOOMFIELD SJ, Midwinter AC, Biggs PJ, French NP, et al
    Long-term colonisation by Campylobacter jejuni within a human host: evolution, antimicrobial resistance and adaptation.
    J Infect Dis. 2017 Nov 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  6. SIBERRY GK, Amzel A, Ramos A, Rivadeneira ED, et al
    Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.
    J Infect Dis. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. BERTAGNOLIO S, Beanland RL, Jordan MR, Doherty M, et al
    The World Health Organization's Response to Emerging Human Immunodeficiency Virus Drug Resistance and a Call for Global Action.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. DUARTE HA, Panpradist N, Beck IA, Lutz B, et al
    Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. MINIOR T, Douglas M, Edgil D, Srivastava M, et al
    The Critical Role of Supply Chains in Preventing Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Settings.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. ZHUKOVA A, Cutino-Moguel T, Gascuel O, Pillay D, et al
    The Role of Phylogenetics as a Tool to Predict the Spread of Resistance.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. SINGH D, Dhummakupt A, Siems L, Persaud D, et al
    Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. CHUN HM, Obeng-Aduasare YF, Broyles LN, Ellenberger D, et al
    Expansion of Viral Load Testing and the Potential Impact on Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  13. CREANGA A, Hang NLK, Cuong VD, Nguyen HT, et al
    Highly Pathogenic Avian Influenza A(H5N1) Viruses at the Animal-Human Interface in Vietnam, 2003-2010.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  14. GUBAREVA LV, Sleeman K, Guo Z, Yang H, et al
    Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  15. ROCKWOOD N, Sirgel F, Streicher E, Warren R, et al
    Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.
    J Infect Dis. 2017;216:632-640.
    PubMed     Text format     Abstract available


  16. MOORE T, Dembry LM, Saag MS
    Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  17. NOGUERA-JULIAN M, Edgil D, Harrigan PR, Sandstrom P, et al
    Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.
    J Infect Dis. 2017 Sep 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. SHAFER RW
    Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
    J Infect Dis. 2017 Sep 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. GODFREY C, Bobkova M, Boucher C, Ravasi G, et al
    Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Sep 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. KISO M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, et al
    Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.
    J Infect Dis. 2017;216:582-593.
    PubMed     Text format     Abstract available


    August 2017
  21. TUITE AR, Gift TL, Chesson HW, Hsu K, et al
    Impact of rapid susceptibility testing and antibiotic selection strategy on the emergence and spread of antibiotic resistance in gonorrhea.
    J Infect Dis. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. OSTROSKY-ZEICHNER L, Andes D
    The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  23. LEWIS RE, Verweij PE
    Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  24. CHOWDHARY A, Sharma C, Meis JF
    Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  25. ARENDRUP MC, Patterson TF
    Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  26. MCCARTHY MW, Kontoyiannis DP, Cornely OA, Perfect JR, et al
    Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  27. PERLIN DS, Wiederhold NP
    Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  28. MCCARTHY MW, Denning DW, Walsh TJ
    Future Research Priorities in Fungal Resistance.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  29. NIELSEN TB, Pantapalangkoor P, Luna BM, Bruhn KW, et al
    Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.
    J Infect Dis. 2017;216:489-501.
    PubMed     Text format     Abstract available


  30. CLUTTER DS, Zhou S, Varghese V, Rhee SY, et al
    Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.
    J Infect Dis. 2017;216:387-391.
    PubMed     Text format     Abstract available


    July 2017
  31. GOLDEN MR, Workowski KA, Bolan G
    Developing a Public Health Response to Mycoplasma genitalium.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  32. MARTIN DH, Manhart LE, Workowski KA
    Mycoplasma genitalium From Basic Science to Public Health: Summary of the Results From a National Institute of Allergy and Infectious Disesases Technical Consultation and Consensus Recommendations for Future Research Priorities.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  33. HORNER PJ, Martin DH
    Mycoplasma genitalium Infection in Men.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  34. BRADSHAW CS, Jensen JS, Waites KB
    New Horizons in Mycoplasma genitalium Treatment.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  35. GAYDOS CA
    Mycoplasma genitalium: Accurate Diagnosis Is Necessary for Adequate Treatment.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  36. BOUCHER HW, Ambrose PG, Chambers HF, Ebright RH, et al
    White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs.
    J Infect Dis. 2017;216:228-236.
    PubMed     Text format     Abstract available


    June 2017
  37. LAVERDE D, Probst I, Romero-Saavedra F, Kropec A, et al
    Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens.
    J Infect Dis. 2017;215:1836-1845.
    PubMed     Text format     Abstract available


    May 2017
  38. JAMMAL J, Zaknoon F, Kaneti G, Hershkovits AS, et al
    Sensitization of Gram-Negative Bacilli to Host Antibacterial Proteins.
    J Infect Dis. 2017;215:1599-1607.
    PubMed     Text format     Abstract available


  39. POPOVICH KJ, Snitkin ES, Hota B, Green SJ, et al
    Genomic and Epidemiological Evidence for Community Origins of Hospital-Onset Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    J Infect Dis. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  40. HAGE E, Wilkie GS, Linnenweber-Held S, Dhingra A, et al
    Characterization of human cytomegalovirus genome diversity in immunocompromised hosts by whole genomic sequencing directly from clinical specimens.
    J Infect Dis. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. KAKIUCHI S, Tsuji M, Nishimura H, Yoshikawa T, et al
    Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients.
    J Infect Dis. 2017;215:865-873.
    PubMed     Text format     Abstract available


  42. MARGOT NA, Wong P, Kulkarni R, White K, et al
    Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    J Infect Dis. 2017;215:920-927.
    PubMed     Text format     Abstract available


  43. MAVE V, Chandanwale A, Kagal A, Khadse S, et al
    High Burden of Antimicrobial Resistance and Mortality Among Adults and Children with Community-Onset Bacterial Infections in India.
    J Infect Dis. 2017 Mar 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. OECHSLIN F, Piccardi P, Mancini S, Gabard J, et al
    Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.
    J Infect Dis. 2017;215:703-712.
    PubMed     Text format     Abstract available


    February 2017
  45. RAY SM
    Preventing Methicillin-Resistant Staphylococcus aureus (MRSA) Disease in Urban US Hospitals-Now for the Hard Part: More Evidence Pointing to the Community as the Source of MRSA Acquisition.
    J Infect Dis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format    


  46. PHILLIPS AN, Stover J, Cambiano V, Nakagawa F, et al
    Impact of HIV drug resistance on HIV/AIDS associated mortality, new infections and antiretroviral therapy program costs in sub-Saharan Africa.
    J Infect Dis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. GEISINGER E, Isberg RR
    Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  48. GOMEZ-SIMMONDS A, Uhlemann AC
    Clinical Implications of Genomic Adaptation and Evolution of Carbapenem-Resistant Klebsiella pneumoniae.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  49. LOGAN LK, Weinstein RA
    The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  50. MURRAY GL, Tsyganov K, Kostoulias XP, Bulach DM, et al
    Global Gene Expression Profile of Acinetobacter baumannii During Bacteremia.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  51. PARKER D
    Impact of Type I and III Interferons on Respiratory Superinfections Due to Multidrug-Resistant Pathogens.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  52. HENRY CS, Rotman E, Lathem WW, Tyo KE, et al
    Generation and Validation of the iKp1289 Metabolic Model for Klebsiella pneumoniae KPPR1.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  53. AHN D, Prince A
    Host-Pathogen Interface: Progress in Understanding the Pathogenesis of Infection Due to Multidrug-Resistant Bacteria in the Intensive Care Unit.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  54. JUAN C, Pena C, Oliver A
    Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  55. KAKIUCHI S, Tsuji M, Nishimura H, Yoshikawa T, et al
    The Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus 1 with the Prognosis in Hematopoietic Stem Cell Transplantation Patients.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


    January 2017
  56. WATERS EM, Rudkin JK, Coughlan S, Clair GC, et al
    Redeploying beta-Lactam Antibiotics as a Novel Antivirulence Strategy for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections.
    J Infect Dis. 2017;215:80-87.
    PubMed     Text format     Abstract available


    December 2016
  57. STEEGEN K, Bronze M, Papathanasopoulos MA, van Zyl G, et al
    Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.
    J Infect Dis. 2016;214:1826-1830.
    PubMed     Text format     Abstract available


    November 2016
  58. PLANET PJ, Diaz L, Rios R, Arias CA, et al
    Global Spread of the Community-Associated Methicillin-Resistant Staphylococcus aureus USA300 Latin American Variant.
    J Infect Dis. 2016;214:1609-1610.
    PubMed     Text format    


    September 2016
  59. KAN H, Imamura M, Uchida T, Hiraga N, et al
    Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  60. YU KO, Randolph AG, Agan AA, Yip WK, et al
    Staphylococcus aureus alpha-toxin Response Distinguishes Respiratory Virus-MRSA Co-infection in Children.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  61. GRAD YH, Harris SR, Kirkcaldy RD, Green AG, et al
    Genomic epidemiology of gonococcal resistance to extended spectrum cephalosporins, macrolides, and fluoroquinolones in the US, 2000-2013.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  62. ANGELO KM, Reynolds J, Karp BE, Hoekstra RM, et al
    Antimicrobial Resistance among Nontyphoidal Salmonella Isolated from Blood in the United States, 2003-2013.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  63. LI L, Cheung A, Bayer AS, Chen L, et al
    The Global Regulon sarA Regulates beta-lactam Antibiotic Resistance In Methicillin-resistant Staphylococcus aureus (MRSA) In Vitro and In Endovascular Infections.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  64. DOSTER RS, Kirk L, Tetz LM, Rogers LM, et al
    Staphylococcus aureus infection of human gestational membranes induces bacterial biofilm formation and host production of cytokines.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  65. BOENDER TS, Hamers RL, Ondoa P, Wellington M, et al
    Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    June 2016
  66. AZARIAN T, Daum RS, Petty LA, Steinbeck JL, et al
    Intra-host evolution of methicillin-resistant Staphylococcus aureus USA300 among individuals with reoccurring skin and soft tissue infections.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  67. WHITE E, Smit E, Churchill D, Collins S, et al
    No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  68. TOLEMAN MS, Reuter S, Coll F, Harrison EM, et al
    Systematic surveillance detects multiple silent introductions and household transmission of methicillin-resistant Staphylococcus aureus USA300 in the east of England.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    March 2016
  69. RUSSO TA, Spellberg B, Johnson JR
    Important Complexities of the Antivirulence Target Paradigm: A Novel Ostensibly Resistance-Avoiding Approach for Treating Infections.
    J Infect Dis. 2016;213:901-3.
    PubMed     Text format     Abstract available


  70. GELFAND MS, Cleveland KO
    Reversion From Methicillin Susceptibility to Methicillin Resistance in Staphylococcus aureus.
    J Infect Dis. 2016.
    PubMed     Text format    


  71. LANIER ER, Foster S, Brundage T, Chou S, et al
    Analysis of Cytomegalovirus DNA Polymerase Gene Mutations in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  72. ARAGRI M, Alteri C, Battisti A, Di Carlo D, et al
    Multiple HBV Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  73. KOBAYASHI SD, Porter AR, Dorward DW, Brinkworth AJ, et al
    Phagocytosis and killing of carbapenem-resistant ST258 Klebsiella pneumoniae by human neutrophils.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    December 2015
  74. ARSHAD M, Goller CC, Pilla D, Schoenen FJ, et al
    Threading the needle: small molecule targeting of a xenobiotic receptor to ablate Escherichia coli polysaccharide capsule expression without altering antibiotic resistance.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  75. L'HUILLIER AG, Abed Y, Petty TJ, Cordey S, et al
    E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.
    J Infect Dis. 2015;212:1726-34.
    PubMed     Text format     Abstract available


    November 2015
  76. SVAROVSKAIA ES, Gane E, Dvory-Sobol H, Martin R, et al
    L159F and V321A Sofosbuvir Resistance Associated HCV NS5B Substitutions.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  77. PENROSE K, Parikh UM, Hamanishi KA, Else L, et al
    Selection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-Acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT040 Trial.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  78. POOLMAN JT, Wacker M
    Extra-intestinal Pathogenic Escherichia coli (ExPEC), a common human pathogen: challenges for vaccine development and progress in the field.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    July 2015
  79. LEIMER N, Rachmuhl C, Palheiros Marques M, Bahlmann AS, et al
    Non-stable Staphylococcus aureus small colony variants are induced by low pH and sensitized to antimicrobial therapy by phagolysosomal alkalinization.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  80. DERACHE A, Wallis CL, Vardhanabhuti S, Bartlett J, et al
    Phenotype, Genotype and Drug Resistance in Subtype C HIV-1 Infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  81. ZHOU N, Hernandez D, Ueland J, Yang X, et al
    NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  82. VAN DER VRIES E, Ip DK, Cowling BJ, Zhang JD, et al
    Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected with Different Influenza B Lineages: the Influenza Resistance Information Study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  83. KWIECINSKI J, Peetermans M, Liesenborghs L, Na M, et al
    Staphylokinase controls Staphylococcus aureus biofilm formation and detachment through host plasminogen activation.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  84. HERMANS LE, Svicher V, Pas SD, Salpini R, et al
    Combined Analysis of the Prevalence of drug Resistant HBV in antiviral therapy Experienced patients in Europe (CAPRE).
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    June 2015
  85. LISCHKA P, Michel D, Zimmermann H
    Characterization of cytomegalovirus breakthrough events in a letermovir (AIC246, MK 8228) phase 2 prophylaxis trial.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


  86. SALVATORE PP, Becerra MC, Zur Wiesch PA, Hinkley T, et al
    Fitness Costs of Drug-resistance Mutations in Multidrug Resistant M. tuberculosis: A Household-based Case-control Study.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


    May 2015
  87. TAMURA D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, et al
    Emergence of multidrug resistant influenza A(H1N1)pdm09 virus variants in an immunocompromised child treated with oseltamivir and zanamivir.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: